Skip to main content

Table 1 Baseline characteristics of FH patients

From: Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

Patient no. Sex Type of FH Mutations Genotype Age at the start of LA (y) LDL-Cat the start of LA (mmol/l) Duration of LA(y) CAD CABG PCI AoS CVD PAD DM
1 F HeFH 50 10,14 16 +
2 M HeFH + p.Gly324AlafsX46 33 8,95 17 + + +
3 M HeFH + p.Ser306X 50 6,70 14 + + + + +
4 M HeFH 60 4,76 20 +
5 M HeFH + p.Cys681X 58 5,47 18 + +
6 F HeFH 52 7,13 14 + + +
7 M HeFH + p.His690ThrfsX19 55 5,60 12 + + +
8 M HeFH + p.Gly396AlafsX54 39 6,05 13
9 F HeFH 50 9,50 21 + + + + + +
10 F HeFH 56 4,50 19 + +
11 F HoFH + p.Gly592Glu/c.2390-lG>A 14 21,30 17 + + +
12 F HoFH + p.Asp492Asn/p.Gly592Glu 20 17,50 27 +
13 M HoFH + p.Gly592Glu/c.2390-lG>A 22 13,92 16 +
14 F ARH + C.143T.C; p.(Phe48Ser) 58 14,90 7 + + + +